__timestamp | Eli Lilly and Company |
---|---|
Tuesday, January 1, 2019 | 122369084370 |
Wednesday, January 1, 2020 | 153244924560 |
Friday, January 1, 2021 | 250521319860.00003 |
Saturday, January 1, 2022 | 329891098240 |
Sunday, January 1, 2023 | 524733508519.99994 |
Unleashing insights
Over the past five years, the pharmaceutical giants NovoNordisk and Eli Lilly have shown remarkable growth in their market capitalizations. This period, from 2019 to 2023, has been transformative for both companies, reflecting their strategic advancements and market dynamics.
Eli Lilly has experienced a staggering increase in market capitalization, growing from approximately $122 billion in 2019 to an impressive $525 billion in 2023. This represents a growth of over 330%, underscoring the company's robust performance and investor confidence.
While the data for NovoNordisk is not explicitly detailed here, the comparison highlights the competitive landscape in the pharmaceutical industry. NovoNordisk, known for its diabetes care products, has also seen significant growth, albeit at a different pace compared to Eli Lilly.
These trends reflect the dynamic nature of the pharmaceutical sector, driven by innovation, market demand, and strategic investments.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters